MMP-14 overexpression correlates with poor prognosis in non-small cell lung cancer

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 9815-9821

  Wang, Yu zhou ^a   Wu, Kun peng ^a,c   Wu, Ai bing ^a   Yang, Zhi cheng ^a   Li, Jin mei ^a   Mo, Yan li ^a   Xu, Meng ^b   Wu, Bin ^a   Yang, Zhi xiong ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

^c Department of Ophthalmology Heyuan People s Hospital   (China)

Author keywords

Biomarker; Immunohistochemistry; Matrix metalloproteinase 14; Non small cell lung cancer; Prognosis

Indexed keywords

MATRIX METALLOPROTEINASE 14; MMP14 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; BIOSYNTHESIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; UPREGULATION;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 14; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84922391188     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2237-x     Document Type: Article

References (30)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:10.3322/caac.21208.
2. She J, Yang P, Hong Q, Bai C. Lung cancer in China: challenges and interventions. Chest. 2013;143(4):1117–26. doi:10.1378/chest.11-2948.
3. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128(1):452–62. doi:10.1378/chest.128.1.452.
4. Deng YP, Li W, Li YL, Xu H, Liang SS, Zhang LH, et al. MT1-MMP up-regulates VEGF expression in human breast carcinoma MCF-7 cells and induces tumor angiogenesis [article in Chinese]. Chin J Oncol. 2009;31(10):727–31.
5. Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD, et al. Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med. 2006;17(4):583–90.
6. Takino T, Tsuge H, Ozawa T, Sato H. MT1-MMP promotes cell growth and ERK activation through c-Src and paxillin in three-dimensional collagen matrix. Biochem Biophys Res Commun. 2010;396(4):1042–7. doi:10.1016/j.bbrc.2010.05.059.
7. Tolde O, Rosel D, Mierke CT, Pankova D, Folk P, Vesely P, et al. Neoplastic progression of the human breast cancer cell line G3S1 is associated with elevation of cytoskeletal dynamics and upregulation of MT1-MMP. Int J Oncol. 2010;36(4):833–9.
8. Suojanen J, Salo T, Koivunen E, Sorsa T, Pirila E. A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth. Cancer Biol Ther. 2009;8(24):2362–70.
9. Xu M, Wang YZ. miR133a suppresses cell proliferation, migration and invasion in human lung cancer by targeting MMP14. Oncol Rep. 2013;30(3):1398–404. doi:10.3892/or.2013.2548.
10. Atkinson JM, Pennington CJ, Martin SW, Anikin VA, Mearns AJ, Loadman PM, et al. Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: correlation of MMP-14 mRNA expression and proteolytic activity. Eur J Cancer. 2007;43(11):1764–71. doi:10.1016/j.ejca.2007.05.009.
11. Demidyuk IV, Shubin AV, Gasanov EV, Kurinov AM, Demkin VV, Vinogradova TV, et al. Alterations in gene expression of proprotein convertases in human lung cancer have a limited number of scenarios. PLoS One. 2013;8(2):e55752. doi:10.1371/journal.pone.0055752.
12. Peng CW, Wang LW, Fang M, Yang GF, Li Y, Pang DW. Combined features based on MT1-MMP expression, CD11b + immunocytes density and LNR predict clinical outcomes of gastric cancer. J Transl Med. 2013;11:153. doi:10.1186/1479-5876-11-153.
13. Akanuma N, Hoshino I, Akutsu Y, Murakami K, Isozaki Y, Maruyama T, et al. MicroRNA-133a regulates the mRNAs of two invadopodia-related proteins, FSCN1 and MMP14, in esophageal cancer. Br J Cancer. 2014;110(1):189–98. doi:10.1038/bjc.2013.676.
14. Tetu B, Brisson J, Wang CS, Lapointe H, Beaudry G, Blanchette C, et al. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res: BCR. 2006;8(3):R28. doi:10.1186/bcr1503.
15. Crispi S, Calogero RA, Santini M, Mellone P, Vincenzi B, Citro G, et al. Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS One. 2009;4(9):e7016. doi:10.1371/journal.pone.0007016.
16. Wang L, Yuan J, Tu Y, Mao X, He S, Fu G, et al. Co-expression of MMP-14 and MMP-19 predicts poor survival in human glioma. Clin Transl Oncol. 2013;15(2):139–45. doi:10.1007/s12094-012-0900-5.
17. Trudel D, Fradet Y, Meyer F, Harel F, Tetu B. Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. Hum Pathol. 2008;39(5):731–9. doi:10.1016/j.humpath.2007.09.021.
18. Zhang H, Liu M, Sun Y, Lu J. MMP-14 can serve as a prognostic marker in patients with supraglottic cancer. Eur Arch Otorhinolaryngol. 2009;266(9):1427–34. doi:10.1007/s00405-009-0943-6.
19. Kondratiev S, Gnepp DR, Yakirevich E, Sabo E, Annino DJ, Rebeiz E, et al. Expression and prognostic role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas. Hum Pathol. 2008;39(3):337–43. doi:10.1016/j.humpath.2007.07.003.
20. Luo WR, Wu AB, Fang WY, Li SY, Yao KT. Nuclear expression of N-cadherin correlates with poor prognosis of nasopharyngeal carcinoma. Histopathology. 2012;61(2):237–46. doi:10.1111/j.1365-2559.2012.04212.x.
21. Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J, et al. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res. 2008;14(21):6996–7003. doi:10.1158/1078-0432.ccr-08-0754.
22. Delassus GS, Cho H, Hoang S, Eliceiri GL. Many new down- and up-regulatory signaling pathways, from known cancer progression suppressors to matrix metalloproteinases, differ widely in cells of various cancers. J Cell Physiol. 2010;224(2):549–58. doi:10.1002/jcp.22157.
23. Chen TY, Li YC, Liu YF, Tsai CM, Hsieh YH, Lin CW, et al. Role of MMP14 gene polymorphisms in susceptibility and pathological development to hepatocellular carcinoma. Ann Surg Oncol. 2011;18(8):2348–56. doi:10.1245/s10434-011-1574-x.
24. Kettunen E, Anttila S, Seppanen JK, Karjalainen A, Edgren H, Lindstrom I, et al. Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet. 2004;149(2):98–106. doi:10.1016/s0165-4608(03)00300-5.
25. Udayakumar TS, Chen ML, Bair EL, Von Bredow DC, Cress AE, Nagle RB, et al. Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta3 chain and induces cell migration. Cancer Res. 2003;63(9):2292–9.
26. Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P, et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci U S A. 1995;92(7):2730–4.
27. Munaut C, Noel A, Hougrand O, Foidart JM, Boniver J, Deprez M. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer J Int du Cancer. 2003;106(6):848–55. doi:10.1002/ijc.11313.
28. Yamamura T, Nakanishi K, Hiroi S, Kumaki F, Sato H, Aida S, et al. Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas. Lung Cancer. 2002;35(3):249–55.
29. Wiegand S, Dunne AA, Muller HH, Mandic R, Barth P, Davis RK, et al. Metaanalysis of the significance of matrix metalloproteinases for lymph node disease in patients with head and neck squamous cell carcinoma. Cancer. 2005;104(1):94–100. doi:10.1002/cncr.21131.
30. Uzui H, Harpf A, Liu M, Doherty TM, Shukla A, Chai NN, et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation. 2002;106(24):3024–30.